Procept Biorobotics Corp (PRCT)

Currency in USD
41.23
+1.88(+4.78%)
Closed·
41.70+0.47(+1.14%)
·
PRCT Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
PRCT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
39.2741.42
52 wk Range
37.12103.81
Key Statistics
Prev. Close
39.35
Open
39.87
Day's Range
39.27-41.42
52 wk Range
37.12-103.81
Volume
727.62K
Average Volume (3m)
1.06M
1-Year Change
-48.64%
Book Value / Share
6.97
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PRCT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
66.22
Upside
+60.62%
Members' Sentiments
Bearish
Bullish
ProTips
7 analysts have revised their earnings downwards for the upcoming period

Procept Biorobotics Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Procept Biorobotics Corp Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. It also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

Procept Biorobotics Corp Earnings Call Summary for Q2/2025

  • Q2 2025 revenue of $79.2M, up 48% YoY; EPS of -$0.35 beats -$0.41 forecast
  • Stock dips 5.05% post-earnings despite beat; trading near 52-week low of $45.37
  • New Hydros robotic platform with AI assistance launched; international expansion targets UK, Japan, Korea
  • FY2025 revenue guidance of $325.5M, up 45% YoY; 210 new US robotic systems expected
  • CEO transition: Larry Wood to replace Reza Zadno; company maintains strong liquidity with 8.95x current ratio
Last Updated: 07/08/2025, 08:48
Read Full Transcript

Compare PRCT to Peers and Sector

Metrics to compare
PRCT
Peers
Sector
Relationship
P/E Ratio
−27.3x−4.3x−0.6x
PEG Ratio
−1.12−0.160.00
Price/Book
5.9x3.2x2.6x
Price / LTM Sales
8.3x3.0x3.3x
Upside (Analyst Target)
54.9%34.2%37.9%
Fair Value Upside
Unlock5.7%3.7%Unlock

Analyst Ratings

9 Buy
3 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 66.22
(+60.62% Upside)

Earnings

Latest Release
Aug 06, 2025
EPS / Forecast
-0.35 / -0.41
Revenue / Forecast
79.20M / 76.12M
EPS Revisions
Last 90 days

PRCT Income Statement

People Also Watch

179.09
ALAB
+0.88%
6.3200
EOSE
+4.98%
44.380
RKLB
+6.86%
16.80
OSCR
+8.95%
47.070
ASTS
+4.65%

FAQ

What Stock Exchange Does Procept Biorobotics Trade On?

Procept Biorobotics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Procept Biorobotics?

The stock symbol for Procept Biorobotics is "PRCT."

What Is the Procept Biorobotics Market Cap?

As of today, Procept Biorobotics market cap is 2.31B.

What Is Procept Biorobotics's Earnings Per Share (TTM)?

The Procept Biorobotics EPS (TTM) is -1.56.

When Is the Next Procept Biorobotics Earnings Date?

Procept Biorobotics will release its next earnings report on 29 Oct 2025.

From a Technical Analysis Perspective, Is PRCT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Procept Biorobotics Stock Split?

Procept Biorobotics has split 0 times.

How Many Employees Does Procept Biorobotics Have?

Procept Biorobotics has 756 employees.

What is the current trading status of Procept Biorobotics (PRCT)?

As of 23 Aug 2025, Procept Biorobotics (PRCT) is trading at a price of 41.23, with a previous close of 39.35. The stock has fluctuated within a day range of 39.27 to 41.42, while its 52-week range spans from 37.12 to 103.81.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.